Jasper Therapeutics (JSPR) Price & Analysis

Compare

1,020 Followers

JSPR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.27 - $26.05

Previous CloseN/A

Volume4.28M

Average Volume (3M)1.01M

Market Cap

$42.81M

Enterprise Value$18.39M

Total Cash (Recent Filing)$48.80M

Total Debt (Recent Filing)$2.59M

Price to Earnings (P/E)―

Beta2.58

Next Earnings

Nov 06, 2025

EPS Estimate

-1.26

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.74

Shares Outstanding15,022,122

10 Day Avg. Volume287,522

30 Day Avg. Volume1,014,840

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.43

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit63.84

Enterprise Value/Ebitda-1.72

Forecast

1Y Price Target

$21.88

Price Target Upside636.70% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

EfficacyBriquilimab continues to show robust efficacy with clean safety across CSU/CIndU, and analyst remains constructive on the outlook despite the recent delay from potential manufacturing issues.

LeadershipDr. Daniel Adelman, an experienced clinical development executive, will assume the role of acting CMO, bringing expertise in immunology and asthmatic conditions.

ValuationAnalyst believes briquilimab has a highly competitive profile at an attractive valuation, hence the Buy recommendation remains.

Bears Say

Competitive PressureDevelopment delays versus competitor and competition from other companies pressure the JSPR story.

Development DelaysThe expected start for the Ph2b CSU study has now been pushed out to mid-'26, placing Jasper ~18-24 months behind the competition.

Workforce ReductionThe company announced a 50% reduction in its workforce, leading to a new headcount of about 22 employees, as a measure to extend the cash runway into 2026.

Jasper Therapeutics News

Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)

“The compelling results we are generating in both CSU and CIndU continue to reinforce our belief that briquilimab...

1d ago

JSPR

Jasper Therapeutics: Promising Clinical Data and Strategic Focus Drive Buy Rating

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Jasper Therapeutics, retaining the price target of...

12h ago

JSPR

Jasper Therapeutics Reports Promising Q2 2025 Results

Jasper Therapeutics, Inc. ( ($JSPR) ) has released its Q2 earnings. Here is a breakdown of the information...

20h ago

JSPR

Jasper Therapeutics Announces Major Corporate Reorganization

Jasper Therapeutics ( ($JSPR) ) has provided an update. On July 8, 2025, Jasper Therapeutics announced a corporate...

1M ago

JSPR

Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria

Jasper Therapeutics (JSPR) announced a corporate reorganization to extend its cash runway, including a workforce reduction of approximately...

1M ago

JSPR

RBC downgrades Jasper Therapeutics on questions about briquilimab

As previously reported, RBC Capital downgraded Jasper Therapeutics (JSPR) to Sector Perform from Outperform with a price target...

1M ago

CLDX

JSPR

Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP

Citizens JMP lowered the firm’s price target on Jasper Therapeutics (JSPR) to $12 from $70 and keeps an...

1M ago

JSPR

Jasper Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital downgraded Jasper Therapeutics (JSPR) to Sector Perform from Outperform with a price target of $5, down...

1M ago

JSPR

Jasper Therapeutics downgraded to Market Perform from Outperform at BMO Capital

BMO Capital downgraded Jasper Therapeutics (JSPR) to Market Perform from Outperform with a price target of $4, down...

1M ago

JSPR

Hold Rating for Jasper Therapeutics Amid Uncertainties in Briquilimab’s Clinical Trials and Competitive Challenges

In a report released today, Kostas Biliouris from BMO Capital downgraded Jasper Therapeutics to a Hold, with a...

1M ago

JSPR

Cantor cuts Jasper Therapeutics to Neutral after briquilimab update

As previously reported, Cantor Fitzgerald downgraded Jasper Therapeutics (JSPR) to Neutral from Overweight with no price target after...

1M ago

JSPR

Jasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald downgraded Jasper Therapeutics (JSPR) to Neutral from Overweight. Published first on TheFly – the ultimate source...

1M ago

JSPR

Buy Rating Maintained for Jasper Therapeutics Amid Manufacturing Setback and Promising Drug Profile

Analyst Justin Zelin of BTIG reiterated a Buy rating on Jasper Therapeutics, reducing the price target to $20.00....

1M ago

JSPR

Jasper Therapeutics price target lowered to $20 from $64 at BTIG

BTIG lowered the firm’s price target on Jasper Therapeutics (JSPR) to $20 from $64 and keeps a Buy...

1M ago

JSPR

JSPR FAQ

What was Jasper Therapeutics, Inc.’s price range in the past 12 months?

Jasper Therapeutics, Inc. lowest stock price was $2.27 and its highest was $26.05 in the past 12 months.

What is Jasper Therapeutics, Inc.’s market cap?

Jasper Therapeutics, Inc.’s market cap is $42.81M.

When is Jasper Therapeutics, Inc.’s upcoming earnings report date?

Jasper Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 83 days.

How were Jasper Therapeutics, Inc.’s earnings last quarter?

Jasper Therapeutics, Inc. released its earnings results on Aug 13, 2025. The company reported -$1.74 earnings per share for the quarter, missing the consensus estimate of -$1.326 by -$0.414.

Is Jasper Therapeutics, Inc. overvalued?

According to Wall Street analysts Jasper Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Jasper Therapeutics, Inc. pay dividends?

Jasper Therapeutics, Inc. does not currently pay dividends.

What is Jasper Therapeutics, Inc.’s EPS estimate?

Jasper Therapeutics, Inc.’s EPS estimate is -1.26.

How many shares outstanding does Jasper Therapeutics, Inc. have?

Jasper Therapeutics, Inc. has 15,022,122 shares outstanding.

What happened to Jasper Therapeutics, Inc.’s price movement after its last earnings report?

Jasper Therapeutics, Inc. reported an EPS of -$1.74 in its last earnings report, missing expectations of -$1.326. Following the earnings report the stock price went up 4.211%.

Which hedge fund is a major shareholder of Jasper Therapeutics, Inc.?

Currently, no hedge funds are holding shares in JSPR

Jasper Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-146.87%

Trailing 12-Months

Asset Growth

-59.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Jasper Therapeutics, Inc.

Jasper Therapeutics (JSPR) is a biotechnology company focused on the development of innovative therapies for diseases of the hematopoietic system, including immunology and oncology conditions. The company is dedicated to advancing its pipeline of novel therapies aimed at improving patient outcomes by targeting the root causes of these diseases. Jasper Therapeutics' lead product candidate is designed to improve the success and safety of hematopoietic cell transplants, which are critical for treating a variety of life-threatening diseases.

Jasper Therapeutics (JSPR) Earnings & Revenues

Historic Earnings Reports

JSPR Stock 12 Month Forecast

Average Price Target

$21.88

▲(636.70% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","66":"$66","17.25":"$17.25","33.5":"$33.5","49.75":"$49.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,17.25,33.5,49.75,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.88,7.658461538461538,12.436923076923076,17.215384615384615,21.993846153846153,26.77230769230769,31.55076923076923,36.32923076923077,41.10769230769231,45.88615384615385,50.66461538461539,55.44307692307692,60.221538461538465,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.88,4.341538461538462,5.803076923076922,7.264615384615384,8.726153846153846,10.187692307692307,11.649230769230769,13.110769230769229,14.572307692307692,16.033846153846152,17.495384615384616,18.956923076923076,20.418461538461536,{"y":21.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.88,2.966153846153846,3.0523076923076924,3.1384615384615384,3.2246153846153844,3.310769230769231,3.396923076923077,3.483076923076923,3.569230769230769,3.6553846153846155,3.7415384615384615,3.827692307692308,3.913846153846154,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.27,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.97,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >